Genmab A/S NASDAQ:GMAB

Founder-led company

Genmab A/S stock price today

$23.82
+2.80
+13.32%
Financial Health
0
1
2
3
4
5
6
7
8
9

Genmab A/S stock price monthly change

-22.29%
month

Genmab A/S stock price quarterly change

-22.29%
quarter

Genmab A/S stock price yearly change

-33.82%
year

Genmab A/S key metrics

Market Cap
13.11B
Enterprise value
16.16B
P/E
31.71
EV/Sales
1.10
EV/EBITDA
2.22
Price/Sales
11.02
Price/Book
5.86
PEG ratio
0.38
EPS
83.49
Revenue
17.76B
EBITDA
6.72B
Income
5.45B
Revenue Q/Q
45.16%
Revenue Y/Y
15.87%
Profit margin
37.83%
Oper. margin
43.56%
Gross margin
0%
EBIT margin
43.56%
EBITDA margin
37.87%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Genmab A/S stock price history

Genmab A/S stock forecast

Genmab A/S financial statements

Genmab A/S (NASDAQ:GMAB): Profit margin
Jun 2023 4.19B 1.35B 32.32%
Sep 2023 4.74B 2.12B 44.88%
Dec 2023 4.67B 640M 13.68%
Mar 2024 4.14B 1.32B 31.98%
Genmab A/S (NASDAQ:GMAB): Analyst Estimates
Sep 2025 5.77B 202.22M 3.5%
Dec 2025 6.02B 202.65M 3.36%
Mar 2026 5.72B 145.32M 2.54%
Jun 2026 6.54B 201.19M 3.07%
  • Analysts Price target

  • Financials & Ratios estimates

Genmab A/S (NASDAQ:GMAB): Earnings per share (EPS)
2022-11-09 1.65 0.53
2023-02-22 0.2354 0.12
Genmab A/S (NASDAQ:GMAB): Debt to assets
Jun 2023 31978000000 3.22B 10.08%
Sep 2023 35238000000 4.12B 11.71%
Dec 2023 35289000000 3.67B 10.43%
Mar 2024 36680000000 4.18B 11.4%
Genmab A/S (NASDAQ:GMAB): Cash Flow
Jun 2023 436M -1.83B 7M
Sep 2023 2.03B 1.00B 20M
Dec 2023 1.67B -442M -22M
Mar 2024 1.51B -1.44B -595M

Genmab A/S alternative data

Genmab A/S (NASDAQ:GMAB): Employee count
Aug 2023 1,846
Sep 2023 2,015
Oct 2023 2,015
Nov 2023 2,015
Dec 2023 2,132
Jan 2024 2,132
Feb 2024 2,132
Mar 2024 2,204
Apr 2024 2,204
May 2024 2,204
Jun 2024 2,286
Jul 2024 2,286

Genmab A/S other data

37.47% -31.74%
of GMAB is owned by hedge funds
24.73M -20.97M
shares is hold by hedge funds
Patent
Application
Filling date: 17 Jul 2020 Issue date: 1 Sep 2022
Application
Filling date: 10 Dec 2021 Issue date: 25 Aug 2022
Application
Filling date: 14 Dec 2021 Issue date: 30 Jun 2022
Grant
Filling date: 14 Jul 2016 Issue date: 14 Jun 2022
Application
Filling date: 16 Jun 2021 Issue date: 9 Jun 2022
Application
Filling date: 7 Jul 2021 Issue date: 2 Jun 2022
Application
Filling date: 22 Dec 2021 Issue date: 12 May 2022
Application
Filling date: 14 Jun 2021 Issue date: 5 May 2022
Application
Filling date: 21 Dec 2021 Issue date: 21 Apr 2022
Application
Filling date: 22 Dec 2021 Issue date: 14 Apr 2022
Insider Compensation
Dr. Jan G.J. van de Winkel (1961) Co-Founder, Pres & Chief Executive Officer
$2,690,000
Mr. Anthony Mancini (1971) Executive Vice President & Chief Operating Officer
$1,390,000
Dr. Judith V. Klimovsky (1958) Executive Vice President & Chief Devel. Officer $1,090,000
Mr. Anthony Pagano (1978) Executive Vice President & Chief Financial Officer
$911,730
Mr. Peter Storm Kristensen (1975) Director of Legal Lead Corporation & Non-Independent Director
$60,780
Dr. Mijke Zachariasse Ph.D. (1974) Director of Protein Production & Chemist and Non-Independent Director
$60,780
Dr. Rima Bawarshi Nassar Ph.D. (1953) Vice President, Head of Global Regulatory Affairs – Oncology & Non-Independent Director
$15,200
Wednesday, 11 December 2024
globenewswire.com
Monday, 9 December 2024
businesswire.com
Sunday, 8 December 2024
businesswire.com
seekingalpha.com
Saturday, 7 December 2024
businesswire.com
Wednesday, 4 December 2024
proactiveinvestors.co.uk
Tuesday, 3 December 2024
globenewswire.com
globenewswire.com
Monday, 25 November 2024
globenewswire.com
Thursday, 21 November 2024
globenewswire.com
Saturday, 9 November 2024
seekingalpha.com
Wednesday, 6 November 2024
globenewswire.com
seekingalpha.com
Tuesday, 5 November 2024
globenewswire.com
globenewswire.com
businesswire.com
Wednesday, 16 October 2024
zacks.com
Tuesday, 15 October 2024
zacks.com
globenewswire.com
Tuesday, 8 October 2024
zacks.com
zacks.com
Friday, 4 October 2024
globenewswire.com
Thursday, 26 September 2024
globenewswire.com
Sunday, 15 September 2024
globenewswire.com
businesswire.com
Tuesday, 10 September 2024
globenewswire.com
Monday, 26 August 2024
globenewswire.com
Friday, 23 August 2024
seekingalpha.com
Monday, 19 August 2024
globenewswire.com
Friday, 16 August 2024
globenewswire.com
  • What's the price of Genmab A/S stock today?

    One share of Genmab A/S stock can currently be purchased for approximately $23.82.

  • When is Genmab A/S's next earnings date?

    Unfortunately, Genmab A/S's (GMAB) next earnings date is currently unknown.

  • Does Genmab A/S pay dividends?

    No, Genmab A/S does not pay dividends.

  • How much money does Genmab A/S make?

    Genmab A/S has a market capitalization of 13.11B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12.87% to 16.47B US dollars. Genmab A/S earned 4.35B US dollars in net income (profit) last year or $0.12 on an earnings per share basis.

  • What is Genmab A/S's stock symbol?

    Genmab A/S is traded on the NASDAQ under the ticker symbol "GMAB".

  • What is Genmab A/S's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Genmab A/S?

    Shares of Genmab A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Genmab A/S's key executives?

    Genmab A/S's management team includes the following people:

    • Dr. Jan G.J. van de Winkel Co-Founder, Pres & Chief Executive Officer(age: 64, pay: $2,690,000)
    • Mr. Anthony Mancini Executive Vice President & Chief Operating Officer(age: 54, pay: $1,390,000)
    • Dr. Judith V. Klimovsky Executive Vice President & Chief Devel. Officer(age: 67, pay: $1,090,000)
    • Mr. Anthony Pagano Executive Vice President & Chief Financial Officer(age: 47, pay: $911,730)
    • Mr. Peter Storm Kristensen Director of Legal Lead Corporation & Non-Independent Director(age: 50, pay: $60,780)
    • Dr. Mijke Zachariasse Ph.D. Director of Protein Production & Chemist and Non-Independent Director(age: 51, pay: $60,780)
    • Dr. Rima Bawarshi Nassar Ph.D. Vice President, Head of Global Regulatory Affairs – Oncology & Non-Independent Director(age: 72, pay: $15,200)
  • Is Genmab A/S founder-led company?

    Yes, Genmab A/S is a company led by its founder Dr. Jan G.J. van de Winkel.

  • How many employees does Genmab A/S have?

    As Jul 2024, Genmab A/S employs 2,286 workers, which is 4% more then previous quarter.

  • When Genmab A/S went public?

    Genmab A/S is publicly traded company for more then 16 years since IPO on 1 Jun 2009.

  • What is Genmab A/S's official website?

    The official website for Genmab A/S is genmab.com.

  • How can i contact Genmab A/S?

    Genmab A/S can be reached via phone at +45 70 20 27 28.

Genmab A/S company profile:

Genmab A/S

genmab.com
Exchange:

NASDAQ

Full time employees:

2,635

Industry:

Biotechnology

Sector:

Healthcare

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Kalvebod Brygge 43
Copenhagen, 1560

CIK: 0001434265
ISIN: US3723032062
CUSIP: 372303206